Press
Ocular Therapeutix Completes PMA Submission for ReSure® Sealant
Ocular Therapeutix, Inc. announced today that it has submitted its Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for ReSure Sealant, a novel ophthalmic medical … [Read more...]
Ocular Therapeutix, Inc. Closes on $23.8 Million Series D Extension
Ocular Therapeutix, Inc. announced today it recently closed a Series D extension round of financing totaling $23.8 million. After considering offers from several new investors, the decision was made … [Read more...]
Richard Lindstrom Joins Board of Directors at Ocular Therapeutix, Inc.
Ocular Therapeutix announced today the appointment of internationally acclaimed ophthalmologist, Richard Lindstrom, M.D., to the company’s Board of Directors. Dr. Lindstrom is a board-certified … [Read more...]
Ocular Therapeutix Demonstrates Two-Month IOP Reduction with Sustained Release Travoprost for the Treatment of Glaucoma
Ocular Therapeutix, Inc. announced promising results of their sustained release travoprost (OTX-TP2) study for the treatment of glaucoma and ocular hypertension. OTX-TP2, a drug-eluting … [Read more...]
Ocular Therapeutix Completes U.S. Pivotal Clinical Trial Enrollment for ReSure® Sealant
Ocular Therapeutix, Inc. announced today it has completed enrollment for its ReSure Sealant Pivotal Clinical Trial, designed to gain Premarket Approval (PMA) by the U.S. Food and Drug Administration … [Read more...]
Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
2 month sustained release drug may improve therapy over topical drop administration. Following encouraging results from Ocular Therapeutix’s travoprost punctum plug feasibility study, the company … [Read more...]
Ocular Therapeutix Discloses Promising Results for Extended Release Treatment of Glaucoma
Intraocular pressure was reduced 23.5% from baseline over the 30-day study period. Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug … [Read more...]
Ocular Therapeutix Commences a Sustained Release Travoprost Punctum Plug Feasibility Study for Treatment of Glaucoma
Study will evaluate reduction in intraocular pressure and product retention. Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug … [Read more...]
Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure™ Sealant
Ocular Therapeutix, Inc. announced today that it has received IDE approval from the U.S. Food and Drug Administration to conduct a pivotal clinical trial with ReSure Sealant, a proprietary synthetic … [Read more...]
Ocular Therapeutix, Inc. Completes Series D Financing to Support Phase II Sustained Drug Delivery Clinical Trials
Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued … [Read more...]